Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones – Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as...
Sutro Biopharma
310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412
